Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 Professor Merab Kokaia, one of CombiGene's scientific founders, speaks at The International Epilepsy CongressThe 34th edition of The International Epilepsy Congress is held from 28 August...
CombiGene’s CEO Jan Nilsson is one of the speakers as “The Future of Swedish and Danish Life Science” celebrates its 10th anniversary
News 2021 2021 2020 2019 2018 2017 2016 2015 On September 2, Jan Nilsson will present his experiences within gene therapy under the heading Gene Therapy, an important tool for precision medicine.Here you will find information about the...
Find it easy
"This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish version, the Swedish version shall prevail. For a complete list of regulatory-related press releases, please refer to the Swedish website"
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.